The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Roadmap for elimination of gastric cancer in Korea

  • Graham, David Y. (Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine)
  • Received : 2014.11.01
  • Accepted : 2014.11.15
  • Published : 2015.03.01
⟨ Previous Next ⟩

Abstract

Most gastric cancers are caused by infection with the common human bacterial pathogen, Helicobacter pylori. It is now accepted that gastric cancer can be prevented and virtually eliminated by H. pylori eradication and this knowledge was responsible for country-wide H. pylori eradication combined with secondary cancer prevention for those with residual risk that was introduced in Japan in 2013. Korea is a high H. pylori prevalence and high gastric cancer incidence country and a good candidate for a gastric cancer elimination program. The presence of an H. pylori infection is now considered as an indication for treatment of the infection. However, antimicrobial drug resistance is common among H. pylori in Korea making effective therapy problematic. Country-wide studies of the local and regional antimicrobial resistance patterns are needed to choose the most appropriate therapies. H. pylori and gastric cancer eradication can be both efficient and cost effective making it possible and practical to make Korea H. pylori and gastric cancer free. There is no reason to delay.

Keywords

References

  1. Graham DY. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World J Gastroenterol 2014;20:5191-5204. https://doi.org/10.3748/wjg.v20.i18.5191
  2. Comfort MW. Gastric acidity before and after development of gastric cancer: its etiologic, diagnostic and prognostic significance. Ann Intern Med 1951;34:1331-1348. https://doi.org/10.7326/0003-4819-34-6-1331
  3. Graham DY, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. J Gastroenterol 2010;45:1-8. https://doi.org/10.1007/s00535-009-0117-8
  4. Cheli R, Perasso A, Giacosa A. Gastritis: A Clinical Review. Berlin: Springer-Verlag, 1987.
  5. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988;48:3554-3560.
  6. Shiotani A, Cen P, Graham DY. Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol 2013;23(6 Pt B):492-501. https://doi.org/10.1016/j.semcancer.2013.07.004
  7. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;1:1273-1275.
  8. International Agency for Research on Cancer, ed. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 100B, Biologic Agents: A Review of Human Carcinogens. Lyon: International Agency for Research on Cancer, 2012:385-435.
  9. International Agency for Research on Cancer, ed. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 61, Schistosomes, Liver Flukes and Helicobacter pylori. Lyon: International Agency for Research on Cancer, 1994.
  10. International Agency for Research on Cancer, ed. IARC Working Group Reports. Vol. 8, Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. Lyon: International Agency for Research on Cancer, 2014.
  11. Asaka M, Kato M, Sakamoto N. Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan. J Gastroenterol 2014;49:1-8. https://doi.org/10.1007/s00535-013-0897-8
  12. Asaka M. A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer 2013;132:1272-1276. https://doi.org/10.1002/ijc.27965
  13. Graham DY, Shiotani A. The time to eradicate gastric cancer is now. Gut 2005;54:735-738. https://doi.org/10.1136/gut.2004.056549
  14. Bracken MB. Risk, Chance, and Causation: Investigating the Origins and Treatment of Disease. New Haven: Yale University Press, 2013.
  15. Hanada K, Uchida T, Tsukamoto Y, et al. Helicobacter pylori infection introduces DNA double-strand breaks in host cells. Infect Immun 2014;82:4182-4189. https://doi.org/10.1128/IAI.02368-14
  16. Hanada K, Graham DY. Helicobacter pylori and the molecular pathogenesis of intestinal-type gastric carcinoma. Expert Rev Anticancer Ther 2014;14:947-954. https://doi.org/10.1586/14737140.2014.911092
  17. Wang C, Weber A, Graham DY. Age, period, and cohort effects on gastric cancer mortality. Dig Dis Sci 2015;60:514-523. https://doi.org/10.1007/s10620-014-3359-0
  18. Lim SH, Kwon JW, Kim N, et al. Prevalence and risk factors of Helicobacter pylori infection in Korea: nationwide multicenter study over 13 years. BMC Gastroenterol 2013;13:104. https://doi.org/10.1186/1471-230X-13-104
  19. Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008;40:650-658. https://doi.org/10.1016/j.dld.2008.02.030
  20. Shin DW, Cho J, Kim SH, et al. Preferences for the "screen and treat" strategy of Helicobacter pylori to prevent gastric cancer in healthy Korean populations. Helicobacter 2013;18:262-269. https://doi.org/10.1111/hel.12039
  21. Park JM, Hahm KB. The Korean perspective of Helicobacter pylori infection: lessons from the Japanese government's policy to prevent gastric cancer. Dig Dis 2014;32:290-294. https://doi.org/10.1159/000357861
  22. Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138-143. https://doi.org/10.1002/ijc.11680
  23. The Research Group for Population-based Cancer Registration in Japan. Cancer incidence and incidence rates in Japan in 1986: estimates based on data from nine population-based cancer registries. Jpn J Clin Oncol 1991;21:318-323. https://doi.org/10.1093/oxfordjournals.jjco.a039478
  24. Chung JW, Lee GH, Han JH, et al. The trends of oneweek first-line and second-line eradication therapy for Helicobacter pylori infection in Korea. Hepatogastroenterology 2011;58:246-250.
  25. Yoon JH, Baik GH, Sohn KM, et al. Trends in the eradication rates of Helicobacter pylori infection for eleven years. World J Gastroenterol 2012;18:6628-6634. https://doi.org/10.3748/wjg.v18.i45.6628
  26. Jung YS, Lee SH, Park CS, et al. Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years. Korean J Gastroenterol 2014;63:82-89. https://doi.org/10.4166/kjg.2014.63.2.82
  27. Jeon HK, Kim GH. Does standard triple therapy still have a role in first-line Helicobacter pylori eradication in Korea? J Korean Med Sci 2014;29:619-620. https://doi.org/10.3346/jkms.2014.29.5.619
  28. Gong EJ, Yun SC, Jung HY, et al. Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change? J Korean Med Sci 2014;29:704-713. https://doi.org/10.3346/jkms.2014.29.5.704
  29. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014;12:177.e3-186.e3. https://doi.org/10.1016/j.cgh.2013.09.016
  30. Wu JY, Liou JM, Graham DY. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol 2014;8:21-28. https://doi.org/10.1586/17474124.2014.859522
  31. Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am 2010;39:465-480. https://doi.org/10.1016/j.gtc.2010.08.007
  32. Lee SY. Future candidates for indications of Helicobacter pylori eradication: do the indications need to be revised? J Gastroenterol Hepatol 2012;27:200-211. https://doi.org/10.1111/j.1440-1746.2011.06961.x

Cited by

  1. Helicobacter Pylori Infection and Related Gastrointestinal Diseases vol.89, pp.2, 2015, https://doi.org/10.3904/kjm.2015.89.2.142
  2. Helicobacter Pylori and Gastric Cancer: Clinical Aspects vol.128, pp.22, 2015, https://doi.org/10.4103/0366-6999.169107
  3. Endoscopic gastritis, serum pepsinogen assay, and Helicobacter pylori infection vol.31, pp.5, 2015, https://doi.org/10.3904/kjim.2016.166
  4. The antibacterial effect of fatty acids on Helicobacter pylori infection vol.31, pp.1, 2015, https://doi.org/10.3904/kjim.2016.31.1.30
  5. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance vol.7, pp.None, 2015, https://doi.org/10.3389/fcimb.2017.00168
  6. Laparoscopic gastrectomy for elderly patients with gastric cancer : A systematic review with meta-analysis vol.97, pp.8, 2015, https://doi.org/10.1097/md.0000000000010007
  7. The eradication of Helicobacter pylori to prevent gastric cancer: a critical appraisal vol.13, pp.1, 2015, https://doi.org/10.1080/17474124.2019.1542299
  8. Analysis of factors associated with recovery of the serum pepsinogen ratio afterHelicobacter pylorieradication: a long-term follow-up study in Korea vol.54, pp.11, 2015, https://doi.org/10.1080/00365521.2019.1686058
  9. Optimized diagnosis of Helicobacter pylori and tailored eradication therapy for preventing gastric cancer: a proposal for SHAKE strategy vol.14, pp.7, 2020, https://doi.org/10.1080/17474124.2020.1770594
  10. Lessons learned from upper gastrointestinal endoscopy in asymptomatic Chinese vol.26, pp.3, 2015, https://doi.org/10.1111/hel.12803